{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:59:48Z","timestamp":1790283588095,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100019004","name":"Deanship of Research, Jordan University of Science and Technology","doi-asserted-by":"publisher","award":["436"],"award-info":[{"award-number":["436"]}],"id":[{"id":"10.13039\/501100019004","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019004","name":"Deanship of Research, Jordan University of Science and Technology","doi-asserted-by":"publisher","award":["2025"],"award-info":[{"award-number":["2025"]}],"id":[{"id":"10.13039\/501100019004","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03489-1","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:08:54Z","timestamp":1783019334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Preparation and Physicochemical Characterization of a Triple Synergistic Nanoplatform Designed for Targeted Subcutaneous Delivery of Sitagliptin with Potential for \u03b2-Cell Preservation"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0640-8085","authenticated-orcid":false,"given":"Mo\u2019tasem M.","family":"Alsmadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9236-2153","authenticated-orcid":false,"given":"Rana","family":"Obaidat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"3489_CR1","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.biopha.2018.12.127","volume":"111","author":"A Ghorbani","year":"2019","unstructured":"Ghorbani A, Rashidi R, Shafiee-Nick R. Flavonoids for preserving pancreatic beta cell survival and function: a mechanistic review. Biomed Pharmacother. 2019;111:947\u201357. https:\/\/doi.org\/10.1016\/j.biopha.2018.12.127.","journal-title":"Biomed Pharmacother"},{"key":"3489_CR2","doi-asserted-by":"publisher","first-page":"426","DOI":"10.4093\/dmj.2014.38.6.426","volume":"38","author":"KY Jung","year":"2014","unstructured":"Jung KY, Kim KM, Lim S. Therapeutic approaches for preserving or restoring pancreatic \u03b2-cell function and mass. Diabetes Metab J. 2014;38:426\u201336. https:\/\/doi.org\/10.4093\/dmj.2014.38.6.426.","journal-title":"Diabetes Metab J"},{"key":"3489_CR3","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.2337\/dc06-0703","volume":"29","author":"P Aschner","year":"2006","unstructured":"Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632\u20137. https:\/\/doi.org\/10.2337\/dc06-0703.","journal-title":"Diabetes Care"},{"key":"3489_CR4","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.2337\/dc07-0627","volume":"30","author":"BJ Goldstein","year":"2007","unstructured":"Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979\u201387. https:\/\/doi.org\/10.2337\/dc07-0627.","journal-title":"Diabetes Care"},{"key":"3489_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ejphar.2009.09.027","volume":"623","author":"J Mu","year":"2009","unstructured":"Mu J, Petrov A, Eiermann GJ, Woods J, Zhou Y-P, Li Z, et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol. 2009;623:148\u201354. https:\/\/doi.org\/10.1016\/j.ejphar.2009.09.027.","journal-title":"Eur J Pharmacol"},{"key":"3489_CR6","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696\u2013705. https:\/\/doi.org\/10.1016\/S0140-6736(06)69705-5.","journal-title":"Lancet"},{"key":"3489_CR7","doi-asserted-by":"publisher","first-page":"762","DOI":"10.2337\/dc08-1797","volume":"32","author":"MC Bunck","year":"2009","unstructured":"Bunck MC, Diamant M, Corn\u00e9r A, Eliasson B, Malloy JL, Shaginian RM, et al. <article-title update=\"added\">One-year treatment with exenatide improves \u03b2-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients. Diabetes Care. 2009;32:762\u20138. https:\/\/doi.org\/10.2337\/dc08-1797.","journal-title":"Diabetes Care"},{"key":"3489_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4158\/ep12100.Or","volume":"19","author":"SK Garg","year":"2013","unstructured":"Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract. 2013;19:19\u201328. https:\/\/doi.org\/10.4158\/ep12100.Or.","journal-title":"Endocr Pract"},{"key":"3489_CR9","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1080\/17425247.2017.1360862","volume":"14","author":"KH Ang","year":"2017","unstructured":"Ang KH, Sherr JL. Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes. Expert Opin Drug Deliv. 2017;14:1113\u201331. https:\/\/doi.org\/10.1080\/17425247.2017.1360862.","journal-title":"Expert Opin Drug Deliv"},{"key":"3489_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1177\/0091270006289850","volume":"46","author":"GA Herman","year":"2006","unstructured":"Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006;46:876\u201386. https:\/\/doi.org\/10.1177\/0091270006289850.","journal-title":"J Clin Pharmacol"},{"key":"3489_CR11","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.2337\/dc06-2545","volume":"30","author":"AJ Bergman","year":"2007","unstructured":"Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007;30:1862\u20134. https:\/\/doi.org\/10.2337\/dc06-2545.","journal-title":"Diabetes Care"},{"key":"3489_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6823-10-7","volume":"10","author":"D Williams-Herman","year":"2010","unstructured":"Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:1\u201321. https:\/\/doi.org\/10.1186\/1472-6823-10-7.","journal-title":"BMC Endocr Disord"},{"key":"3489_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"273","author":"J Green","year":"2017","unstructured":"Green J. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;273:232\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1501352.","journal-title":"N Engl J Med"},{"key":"3489_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2020.151110","volume":"99","author":"GZ Cong","year":"2020","unstructured":"Cong GZ, Ghosh KK, Mishra S, Guly\u00e1s M, Kov\u00e1cs T, M\u00e1th\u00e9 D, et al. Targeted pancreatic beta cell imaging for early diagnosis. Eur J Cell Biol. 2020;99. https:\/\/doi.org\/10.1016\/j.ejcb.2020.151110.","journal-title":"Eur J Cell Biol"},{"key":"3489_CR15","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.1007\/s11356-021-15905-z","volume":"29","author":"IM Alhazza","year":"2022","unstructured":"Alhazza IM, Ebaid H, Omar MS, Hassan I, Habila MA, Al-Tamimi J, et al. Supplementation with selenium nanoparticles alleviates diabetic nephropathy during pregnancy in the diabetic female rats. Environ Sci Pollut Res Int. 2022;29:5517\u201325. https:\/\/doi.org\/10.1007\/s11356-021-15905-z.","journal-title":"Environ Sci Pollut Res Int"},{"key":"3489_CR16","doi-asserted-by":"publisher","first-page":"8956","DOI":"10.1021\/ic301050v","volume":"51","author":"B Yu","year":"2012","unstructured":"Yu B, Zhang Y, Zheng W, Fan C, Chen T. Positive surface charge enhances selective cellular uptake and anticancer efficacy of selenium nanoparticles. Inorg Chem. 2012;51:8956\u201363. https:\/\/doi.org\/10.1021\/ic301050v.","journal-title":"Inorg Chem"},{"key":"3489_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-025-01991-w","author":"RM Yehia","year":"2025","unstructured":"Yehia RM, Ossama M, Elosaily GH, Fayez AM, Amer RI, Attia DA. Biodegradable microneedles for transdermal sitagliptin delivery: in vivo insights into enhanced diabetes management. Drug Deliv Transl Res. 2025. https:\/\/doi.org\/10.1007\/s13346-025-01991-w.","journal-title":"Drug Deliv Transl Res"},{"key":"3489_CR18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.22270\/jddt.v9i4-s.3347","volume":"9","author":"KV Shukla","year":"2019","unstructured":"Shukla KV, Swamy M, Pathak R. Formulation, development and characterization of transdermal patches of sitagliptin phosphate. JDDT. 2019;9:408\u201313. https:\/\/doi.org\/10.22270\/jddt.v9i4-s.3347.","journal-title":"JDDT"},{"key":"3489_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ijpharm.2008.01.015","volume":"356","author":"BR Gedulin","year":"2008","unstructured":"Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, et al. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm. 2008;356:231\u20138. https:\/\/doi.org\/10.1016\/j.ijpharm.2008.01.015.","journal-title":"Int J Pharm"},{"key":"3489_CR20","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/bcp.13135","volume":"83","author":"B Cirincione","year":"2017","unstructured":"Cirincione B, Mager DE. Population pharmacokinetics of exenatide. Br J Clin Pharmacol. 2017;83:517\u201326. https:\/\/doi.org\/10.1111\/bcp.13135.","journal-title":"Br J Clin Pharmacol"},{"key":"3489_CR21","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s12272-001-1247-9","volume":"31","author":"HG Jo","year":"2008","unstructured":"Jo HG, Min KH, Nam TH, Na SJ, Park JH, Jeong SY. Prolonged antidiabetic effect of zinc-crystallized insulin loaded glycol chitosan nanoparticles in type 1 diabetic rats. Arch Pharm Res. 2008;31:918\u201323. https:\/\/doi.org\/10.1007\/s12272-001-1247-9.","journal-title":"Arch Pharm Res"},{"key":"3489_CR22","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1021\/acsptsci.3c00218","volume":"6","author":"C Cristelo","year":"2023","unstructured":"Cristelo C, Nunes R, Pinto S, Marques JM, Gama FM, Sarmento B. Targeting \u03b2 cells with cathelicidin nanomedicines improves insulin function and pancreas regeneration in type 1 diabetic rats. ACS Pharmacol Transl Sci. 2023;6:1544\u201360. https:\/\/doi.org\/10.1021\/acsptsci.3c00218.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3489_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s12011-022-03140-7","volume":"201","author":"OAR Abozaid","year":"2023","unstructured":"Abozaid OAR, El-Sonbaty SM, Hamam NMA, Farrag MA, Kodous AS. Chitosan-encapsulated nano-selenium targeting TCF7L2, PPAR\u03b3, and CAPN10 genes in diabetic rats. Biol Trace Elem Res. 2023;201:306\u201323. https:\/\/doi.org\/10.1007\/s12011-022-03140-7.","journal-title":"Biol Trace Elem Res"},{"key":"3489_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ijpharm.2009.07.001","volume":"381","author":"A Hafner","year":"2009","unstructured":"Hafner A, Lovri\u0107 J, Voinovich D, Filipovi\u0107-Gr\u010di\u0107 J. Melatonin-loaded lecithin\/chitosan nanoparticles: physicochemical characterisation and permeability through Caco-2 cell monolayers. Int J Pharm. 2009;381:205\u201313. https:\/\/doi.org\/10.1016\/j.ijpharm.2009.07.001.","journal-title":"Int J Pharm"},{"key":"3489_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.matlet.2020.128818","volume":"282","author":"H Jafari","year":"2021","unstructured":"Jafari H, Hassanpour M, Akbari A, Rezaie J, Gohari G, Mahdavinia GR, et al. Characterization of pH-sensitive chitosan\/hydroxypropyl methylcellulose composite nanoparticles for delivery of melatonin in cancer therapy. Mater Lett. 2021;282. https:\/\/doi.org\/10.1016\/j.matlet.2020.128818.","journal-title":"Mater Lett"},{"key":"3489_CR26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.5530\/jyp.2023.15.42","volume":"15","author":"N Ahmad","year":"2023","unstructured":"Ahmad N, Khalid MS, Al Ramadhan AM, Al Hammad MR, Khan MF, Almalki ZS, et al. Preparation of melatonin nanoparticles and their enhancement of lungs bioavailability in the treatment of lungs cancer. JYP. 2023;15:314\u201325. https:\/\/doi.org\/10.5530\/jyp.2023.15.42.","journal-title":"JYP"},{"key":"3489_CR27","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ijpharm.2015.11.028","volume":"496","author":"B Topal","year":"2015","unstructured":"Topal B, Alt\u0131ndal D\u00c7, G\u00fcm\u00fc\u015fderelio\u011flu M. Melatonin\/HP\u03b2CD complex: microwave synthesis, integration with chitosan scaffolds and inhibitory effects on MG-63 cells. Int J Pharm. 2015;496:801\u201311. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.11.028.","journal-title":"Int J Pharm"},{"key":"3489_CR28","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3390\/pharmaceutics16070871","volume":"16","author":"CN Cheaburu-Yilmaz","year":"2024","unstructured":"Cheaburu-Yilmaz CN, Atmaca K, Yilmaz O, Orhan H. Development, characterization, and evaluation of potential systemic toxicity of a novel oral melatonin formulation. Pharmaceutics. 2024;16:871. https:\/\/doi.org\/10.3390\/pharmaceutics16070871.","journal-title":"Pharmaceutics"},{"key":"3489_CR29","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3109\/02652048.2011.622053","volume":"28","author":"A Hafner","year":"2011","unstructured":"Hafner A, Lovri\u0107 J, Pepi\u0107 I, Filipovi\u0107-Gr\u010di\u0107 J. Lecithin\/chitosan nanoparticles for transdermal delivery of melatonin. J Microencapsul. 2011;28:807\u201315. https:\/\/doi.org\/10.3109\/02652048.2011.622053.","journal-title":"J Microencapsul"},{"key":"3489_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/21691401.2017.1411933","volume":"46","author":"MA Jahangir","year":"2018","unstructured":"Jahangir MA, Khan R, Sarim Imam S. Formulation of sitagliptin-loaded oral polymeric nano scaffold: process parameters evaluation and enhanced anti-diabetic performance. Artif Cells Nanomed Biotechnol. 2018;46:66\u201378. https:\/\/doi.org\/10.1080\/21691401.2017.1411933.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"3489_CR31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","volume":"12","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010;12:263\u201371. https:\/\/doi.org\/10.1208\/s12248-010-9185-1.","journal-title":"AAPS J"},{"key":"3489_CR32","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.3390\/ma12152351","volume":"12","author":"NCF Stofella","year":"2019","unstructured":"Stofella NCF, Veiga A, Oliveira LJ, Montin EF, Andreazza IF, Carvalho Filho MAS, et al. Solid-state characterization of different crystalline forms of sitagliptin. Materials. 2019;12:2351. https:\/\/doi.org\/10.3390\/ma12152351.","journal-title":"Materials"},{"key":"3489_CR33","doi-asserted-by":"publisher","first-page":"3950942","DOI":"10.1155\/2019\/3950942","volume":"2019","author":"N SreeHarsha","year":"2019","unstructured":"SreeHarsha N, Ramnarayanan C, Al-Dhubiab BE, Nair AB, Hiremath JG, Venugopala KN, et al. Mucoadhesive particles: a novel, prolonged-release nanocarrier of sitagliptin for the treatment of diabetics. Biomed Res Int. 2019;2019:3950942. https:\/\/doi.org\/10.1155\/2019\/3950942.","journal-title":"Biomed Res Int"},{"key":"3489_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemosphere.2022.134790","volume":"301","author":"C Krishnaraj","year":"2022","unstructured":"Krishnaraj C, Radhakrishnan S, Ramachandran R, Ramesh T, Kim B-S, Yun S-I. In vitro toxicological assessment and biosensing potential of bioinspired chitosan nanoparticles, selenium nanoparticles, chitosan\/selenium nanocomposites, silver nanoparticles and chitosan\/silver nanocomposites. Chemosphere. 2022;301. https:\/\/doi.org\/10.1016\/j.chemosphere.2022.134790.","journal-title":"Chemosphere"},{"key":"3489_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122863","volume":"636","author":"H Liu","year":"2023","unstructured":"Liu H, Wang B, Xing M, Meng F, Zhang S, Yang G, et al. Thermal stability of exenatide encapsulated in stratified dissolving microneedles during storage. Int J Pharm. 2023;636. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122863.","journal-title":"Int J Pharm"},{"key":"3489_CR36","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.carbpol.2015.06.064","volume":"132","author":"W Chen","year":"2015","unstructured":"Chen W, Li Y, Yang S, Yue L, Jiang Q, Xia W. Synthesis and antioxidant properties of chitosan and carboxymethyl chitosan-stabilized selenium nanoparticles. Carbohydr Polym. 2015;132:574\u201381. https:\/\/doi.org\/10.1016\/j.carbpol.2015.06.064.","journal-title":"Carbohydr Polym"},{"key":"3489_CR37","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.ijbiomac.2020.08.027","volume":"162","author":"VLR Correa","year":"2020","unstructured":"Correa VLR, Martins JA, de Souza TR, Rincon G, Miguel MP, de Menezes LB, et al. Melatonin loaded lecithin-chitosan nanoparticles improved the wound healing in diabetic rats. Int J Biol Macromol. 2020;162:1465\u201375. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.08.027.","journal-title":"Int J Biol Macromol"},{"key":"3489_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.887402","volume":"13","author":"J McCright","year":"2022","unstructured":"McCright J, Naiknavare R, Yarmovsky J, Maisel K. Targeting lymphatics for nanoparticle drug felivery. Front Pharmacol. 2022;13. https:\/\/doi.org\/10.3389\/fphar.2022.887402.","journal-title":"Front Pharmacol"},{"key":"3489_CR39","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.mattod.2013.11.003","volume":"16","author":"J Liu","year":"2013","unstructured":"Liu J, Yu M, Zhou C, Zheng J. Renal clearable inorganic nanoparticles: a new frontier of bionanotechnology. Mater Today. 2013;16:477\u201386. https:\/\/doi.org\/10.1016\/j.mattod.2013.11.003.","journal-title":"Mater Today"},{"key":"3489_CR40","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1021\/acs.molpharmaceut.8b00292","volume":"15","author":"NM Gulati","year":"2018","unstructured":"Gulati NM, Stewart PL, Steinmetz NF. Bioinspired shielding strategies for nanoparticle drug delivery applications. Mol Pharm. 2018;15:2900\u20139. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00292.","journal-title":"Mol Pharm"},{"key":"3489_CR41","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1038\/am.2013.79","volume":"6","author":"J Wang","year":"2014","unstructured":"Wang J, Hu Z, Xu J, Zhao Y. Therapeutic applications of low-toxicity spherical nanocarbon materials. NPG Asia Mater. 2014;6:e84. https:\/\/doi.org\/10.1038\/am.2013.79.","journal-title":"NPG Asia Mater"},{"key":"3489_CR42","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1002\/adhm.201500441","volume":"4","author":"R Agarwal","year":"2015","unstructured":"Agarwal R, Jurney P, Raythatha M, Singh V, Sreenivasan SV, Shi L, et al. Effect of shape, size, and aspect ratio on nanoparticle penetration and distribution inside solid tissues using 3D spheroid models. Adv Healthc Mater. 2015;4:2269\u201380. https:\/\/doi.org\/10.1002\/adhm.201500441.","journal-title":"Adv Healthc Mater"},{"key":"3489_CR43","doi-asserted-by":"publisher","first-page":"9652","DOI":"10.3390\/ijms22179652","volume":"22","author":"V Miku\u0161ov\u00e1","year":"2021","unstructured":"Miku\u0161ov\u00e1 V, Miku\u0161 P. Advances in chitosan-based nanoparticles for drug delivery. Int J Mol Sci. 2021;22:9652. https:\/\/doi.org\/10.3390\/ijms22179652.","journal-title":"Int J Mol Sci"},{"key":"3489_CR44","unstructured":"Ch\u00e1vez JGD, V\u00e1squez KM, Pel\u00e1ez JPS. Solid forms of sitagliptin. U.S. Patent. 2019;10,301,316"},{"key":"3489_CR45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.xphs.2021.09.031","volume":"111","author":"NA Charoo","year":"2022","unstructured":"Charoo NA, Abdallah DB, Bakheit AA, Haque KU, Hassan HA, Abrahamsson B, et al. Biowaiver monograph for immediate-release solid oral dosage forms: sitagliptin phosphate monohydrate. J Pharm Sci. 2022;111:2\u201313. https:\/\/doi.org\/10.1016\/j.xphs.2021.09.031.","journal-title":"J Pharm Sci"},{"key":"3489_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ma12244239","volume":"12","author":"AB Nair","year":"2019","unstructured":"Nair AB, Sreeharsha N, Al-Dhubiab BE, Hiremath JG, Shinu P, Attimarad M, et al. HPMC- and PLGA-based nanoparticles for the mucoadhesive delivery of sitagliptin: optimization and in vivo evaluation in rats. Materials (Basel). 2019;12. https:\/\/doi.org\/10.3390\/ma12244239.","journal-title":"Materials (Basel)"},{"key":"3489_CR47","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3390\/pharmaceutics15051510","volume":"15","author":"M Barbosa","year":"2023","unstructured":"Barbosa M, Alves PM, Costa F, Monteiro C, Parreira P, Teixeira C, et al. Influence of immobilization strategies on the antibacterial properties of antimicrobial peptide-chitosan coatings. Pharmaceutics. 2023;15:1510. https:\/\/doi.org\/10.3390\/pharmaceutics15051510.","journal-title":"Pharmaceutics"},{"key":"3489_CR48","doi-asserted-by":"publisher","first-page":"114","DOI":"10.18231\/j.ctppc.2024.025","volume":"6","author":"VS Adhao","year":"2024","unstructured":"Adhao VS, Ambhore JP, Bhuskat AD, Talokar DV. Comparative in-vitro dissolution study of some sitagliptin generic tablets under biowaiver conditions by UV-Spectroscopy. Curr trends Pharm Pharm Chem. 2024;6:114\u201321. https:\/\/doi.org\/10.18231\/j.ctppc.2024.025.","journal-title":"Curr trends Pharm Pharm Chem"},{"key":"3489_CR49","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3390\/pharmaceutics15051455","volume":"15","author":"J Weng","year":"2023","unstructured":"Weng J, Durand A, Desobry S. Chitosan-based particulate carriers: structure, production and corresponding controlled release. Pharmaceutics. 2023;15:1455. https:\/\/doi.org\/10.3390\/pharmaceutics15051455.","journal-title":"Pharmaceutics"},{"key":"3489_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251786","volume":"16","author":"JM Araujo","year":"2021","unstructured":"Araujo JM, Fortes-Silva R, Pola CC, Yamamoto FY, Gatlin DM 3rd, Gomes CL. Delivery of selenium using chitosan nanoparticles: synthesis, characterization, and antioxidant and growth effects in Nile tilapia (Orechromis niloticus). PLoS One. 2021;16. https:\/\/doi.org\/10.1371\/journal.pone.0251786.","journal-title":"PLoS One"},{"key":"3489_CR51","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/pharmaceutics12040300","volume":"12","author":"K Prabahar","year":"2020","unstructured":"Prabahar K, Udhumansha U, Qushawy M. Optimization of thiolated chitosan nanoparticles for the enhancement of in vivo hypoglycemic efficacy of sitagliptin in streptozotocin-induced diabetic rats. Pharmaceutics. 2020;12:300. https:\/\/doi.org\/10.3390\/pharmaceutics12040300.","journal-title":"Pharmaceutics"},{"key":"3489_CR52","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3390\/pharmaceutics15051364","volume":"15","author":"IS Bayer","year":"2023","unstructured":"Bayer IS. Controlled drug release from nanoengineered polysaccharides. Pharmaceutics. 2023;15:1364. https:\/\/doi.org\/10.3390\/pharmaceutics15051364.","journal-title":"Pharmaceutics"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03489-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03489-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03489-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:04:53Z","timestamp":1790280293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03489-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["3489"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03489-1","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"250"}}